🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

RecruitingPhase 4Ages 45 Years - 79 YearsAllXueQing Yu
NCT03264352 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular and cerebrovascular events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial, IPAD in brief, is a randomized, open-label, parallel-designed, multicenter study involving nearly 12,000 patients to be recruited and to be followed up for a median of four years. IPAD tests the hypothesis that antihypertensive medications in adults with type 2 diabetes, whose seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic, results in 20% difference in the incidence of major adverse cardiovascular and cerebrovascular events. During follow-up for participants in the intensive group, the sitting systolic pressure should be decreased to below 120 mm Hg, by titration and combination of the study medications of an angiotensin type-1 receptor blocker Allisa

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * irrespective of sex; * aged between 45 and 79 years; * with office-measured seated BP 120-139 mm Hg systolic and below 90 mm Hg diastolic; * diagnosed of type 2 diabetes mellitus (T2DM), currently on diabetic therapy; * informed consent provided and long-term follow-up possible Exclusion Criteria: * poor control of blood glucose, HbA1c \> 10.0% * administration of any antihypertensive medications within 1 month; * a history of hypoglycemic coma / seizure; * confirmed diagnosis of type 1 diabetes mellitus; * alanine-aminotransferase (ALT) or aspartate-aminotransferase (AST) over three times the upper limit of normal; * estimated glomerular filtration rate \< 45 ml/min/1.73m2; * a history of congestive heart failure with left ventricular ejection fraction \< 40%; * coronary artery disease requiring RAS blockers for secondary prevention; * acute on-set of stroke within 6 months prior to randomization; * a ratio of urinary albumin (in mg/L) to urinary creatinine (in g/L) (ACR) ≥ 300 mg/g; * known contraindications for the active study medications; * a history of psychological or mental disorder; * pregnancy or currently planning to have babies or lactation; * severe diseases such as severe heart diseases; * an expected residual life span less than 3 years; * a malignancy that clinical investigators consider as unsuitable to participate; * currently participating in another clinical trial.
💊

What it tests

  • Allisartan Isoproxil
  • Amlodipine 5mg
  • Standard treatment by current guideline
📍

Where

1 site
Guangdong General Hospital
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy